NCT01496313 2025-10-03
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
Phase 4 Completed
Clinical Trials
10 trialsNCT01298323 2025-04-24
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT01661179 2016-12-05
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Sanofi
Phase 1/2 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00807170 2016-08-29
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
Sanofi
Phase 1 Terminated
NCT00047840 2016-08-25
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
Sanofi
Phase 2 Completed
NCT00507091 2016-08-25
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Phase 1 Completed
NCT00034918 2016-08-24
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
Sanofi
Phase 2 Completed
NCT00059722 2016-08-24
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Sanofi
Phase 2 Completed